Overview
Lombard Medical Technologies (LMT) develops, manufactures and markets stent grafts for the treatment of abdominal and thoracic aortic aneurysms, endovascular stapling devices for the fixation of stent grafts and percutaneous heart valves, and develops drug delivery coatings. The Company was established in July 2000 and currently employs over 50 people at Didcot and Ayrshire in the UK and in the USA. The Company also has trade investments in an emerging medical device company.
Lombard Medical Technologies PLC is listed on the London Stock Exchange (AIM) under the symbol LMT. The company is Incorporated in England and Wales under Reg No. 4636949.
Cardiovascular Division
The most significant and immediate potential comes from our stent graft technology for the repair of abdominal aortic aneurysms, a market currently valued at over $400 million worldwide. This is expected to rise to $1 billion by 2010.
Over recent years, the use of stent grafts has provided a much less aggressive alternative to open surgery repair, resulting in shorter stays in hospital and better clinical outcomes.
LMT has developed a stent graft that is fixed securely to the aorta, preventing migration, and is flexible enough to bend without kinking in severely angulated aortas. This allows physicians to provide treatment to a group of otherwise untreatable patients. This, combined with clinical outcomes that are equivalent or better in easier-to-treat cases, should enable LMT to achieve a significant share of this growing market.
Polymer Coatings Division
Lombard Medical has sold the goodwill, contractual rights and intellectual property of its polymer coatings business to Bayer MaterialScience AG (“BMS”) with the remaining assets to be sold to Bayer Plc”.
This divestment is part of Lombard Medical’s strategy to focus its resources on Aorfix™, its unique endovascular stent graft for the treatment of abdominal aortic aneurysms.
Updated December 2009
